featured
Ublituximab Plus Ibrutinib vs Ibrutinib Alone for Patients With Relapsed or Refractory High-Risk CLL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ublituximab Plus Ibrutinib Versus Ibrutinib Alone for Patients With Relapsed or Refractory High-Risk Chronic Lymphocytic Leukaemia (GENUINE): A Phase 3, Multicentre, Open-Label, Randomised Trial
Lancet Haematol 2021 Feb 22;[EPub Ahead of Print], JP Sharman, DM Brander, AR Mato, N Ghosh, SJ Schuster, S Kambhampati, JM Burke, F Lansigan, MT Schreeder, SD Lunin, A Zweibach, M Shtivelband, PM Travis, JC Chandler, KS Kolibaba, P Sportelli, HP Miskin, MS Weiss, IW FlinnFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.